$GTHP
GUIDED THERAPEUTICS INC

2023 Q3 Form 10-Q Financial Statement

#000147793223005869 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $44.00K
YoY Change -100.0% 780.0%
Cost Of Revenue $4.000K $33.00K
YoY Change 3200.0%
Gross Profit -$4.000K $11.00K
YoY Change -233.33% 175.0%
Gross Profit Margin 25.0%
Selling, General & Admin $550.0K $1.450M
YoY Change -54.88% 103.65%
% of Gross Profit 13181.82%
Research & Development $69.00K $66.00K
YoY Change 762.5% 633.33%
% of Gross Profit 600.0%
Depreciation & Amortization $0.00 $3.000K
YoY Change -100.0%
% of Gross Profit 27.27%
Operating Expenses $619.0K $1.516M
YoY Change -49.55% 110.26%
Operating Profit -$623.0K -$1.505M
YoY Change -49.1% 109.9%
Interest Expense $71.00K $69.00K
YoY Change -54.19% -73.05%
% of Operating Profit
Other Income/Expense, Net -$54.00K -$52.00K
YoY Change -144.26% -75.12%
Pretax Income -$677.0K -$1.557M
YoY Change -38.57% 68.14%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$677.0K -$1.557M
YoY Change -161.43% 68.14%
Net Earnings / Revenue -3538.64%
Basic Earnings Per Share -$0.01 -$0.03
Diluted Earnings Per Share -$0.01 -$0.03
COMMON SHARES
Basic Shares Outstanding 51.29M shares 51.01M shares
Diluted Shares Outstanding 51.47M shares 50.97M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $730.0K $1.358M
YoY Change -72.93% 204.48%
Cash & Equivalents $731.0K $1.358M
Short-Term Investments
Other Short-Term Assets $192.0K $91.00K
YoY Change 13.61% 54.24%
Inventory $648.0K $573.0K
Prepaid Expenses
Receivables $7.000K $7.000K
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.578M $2.029M
YoY Change -54.8% 83.95%
LONG-TERM ASSETS
Property, Plant & Equipment $35.00K $36.00K
YoY Change -16.67% -20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $17.00K $17.00K
YoY Change 0.0% 0.0%
Total Long-Term Assets $299.0K $319.0K
YoY Change -21.32% -20.25%
TOTAL ASSETS
Total Short-Term Assets $1.578M $2.029M
Total Long-Term Assets $299.0K $319.0K
Total Assets $1.877M $2.348M
YoY Change -51.51% 56.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.153M $2.128M
YoY Change -2.89% -11.48%
Accrued Expenses $807.0K $971.0K
YoY Change -23.14% -19.49%
Deferred Revenue
YoY Change
Short-Term Debt $1.270M $1.240M
YoY Change 85.13% 228.04%
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $4.834M $4.936M
YoY Change -6.06% -17.68%
LONG-TERM LIABILITIES
Long-Term Debt $510.0K $525.0K
YoY Change -46.75%
Other Long-Term Liabilities $180.0K $202.0K
YoY Change -32.58% -29.62%
Total Long-Term Liabilities $693.0K $727.0K
YoY Change -49.64% -42.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.834M $4.936M
Total Long-Term Liabilities $693.0K $727.0K
Total Liabilities $5.527M $5.663M
YoY Change -15.26% -22.09%
SHAREHOLDERS EQUITY
Retained Earnings -$150.6M -$149.9M
YoY Change 3.54% 3.8%
Common Stock $3.439M $3.438M
YoY Change 0.2% 0.64%
Preferred Stock
YoY Change
Treasury Stock (at cost) $132.0K $132.0K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity -$3.650M -$3.315M
YoY Change
Total Liabilities & Shareholders Equity $1.877M $2.348M
YoY Change -51.51% 56.22%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$677.0K -$1.557M
YoY Change -161.43% 68.14%
Depreciation, Depletion And Amortization $0.00 $3.000K
YoY Change -100.0%
Cash From Operating Activities -$470.0K -$438.0K
YoY Change -23.2% 25.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -150.0K -41.00K
YoY Change -105.24% -147.13%
NET CHANGE
Cash From Operating Activities -470.0K -438.0K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities -150.0K -41.00K
Net Change In Cash -620.0K -479.0K
YoY Change -127.54% 71.68%
FREE CASH FLOW
Cash From Operating Activities -$470.0K -$438.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
gthp Conversion Of Series F Preferred Shares Into Common Stock
ConversionOfSeriesFPreferredSharesIntoCommonStock
296000 usd
CY2019Q3 gthp Escrow Agent Rate Per Share
EscrowAgentRatePerShare
1.90
CY2023Q2 gthp Long Term Debt Related Parties
LongTermDebtRelatedParties
525000 usd
CY2022Q4 gthp Long Term Debt Related Parties
LongTermDebtRelatedParties
83000 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51011000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48596000 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3437000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
138090000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
132000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-147359000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3315000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2883000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3366000 usd
us-gaap Profit Loss
ProfitLoss
1432000 usd
us-gaap Depreciation
Depreciation
0 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
65000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
78000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1683000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
167000 usd
gthp Change In Fair Value Of Derivatives
ChangeInFairValueOfDerivatives
-5000 usd
gthp Change In Fair Value Of Derivatives
ChangeInFairValueOfDerivatives
-8000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
37000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
33000 usd
gthp Gain From Forgiveness Of Debt
GainFromForgivenessOfDebt
-52000 usd
gthp Gain From Forgiveness Of Debt
GainFromForgivenessOfDebt
-75000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-11000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-157000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-25000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
46000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
317000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-173000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
74000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-38000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-32000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-64000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
175000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
195000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
495000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
213000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
133000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-18000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
643000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1358000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
446000 usd
us-gaap Interest Paid
InterestPaid
47000 usd
us-gaap Interest Paid
InterestPaid
14000 usd
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
82000 usd
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
629000 usd
gthp Deemed Dividends For Warrant Exchanges
DeemedDividendsForWarrantExchanges
65000 usd
gthp Deemed Dividends For Warrant Exchanges
DeemedDividendsForWarrantExchanges
0 usd
gthp Conversion Of Series F2 Preferred Shares Into Common Stock
ConversionOfSeriesF2PreferredSharesIntoCommonStock
14000 usd
gthp Schedule Of Fair Value Warrants Issued Under Black Scholes Option Pricing Model Table Textblock
ScheduleOfFairValueWarrantsIssuedUnderBlackScholesOptionPricingModelTableTextblock
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.9</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">290.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>
gthp Schedule Of Weighted Average Remaining Lease Term And Discount Rate
ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(in thousands)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average remaining lease term (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.9</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.4</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average discount rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>
gthp Schedule Of Fair Value Of The Warrants Using The Black Scholes Option Pricing Model
ScheduleOfFairValueOfTheWarrantsUsingTheBlackScholesOptionPricingModel
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">108.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.3</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>
dei Entity Central Index Key
EntityCentralIndexKey
0000924515
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
818000 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48596000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51011000 shares
CY2022Q4 us-gaap Common Unit Outstanding
CommonUnitOutstanding
48595715 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Entity File Number
EntityFileNumber
000-22179
dei Entity Registrant Name
EntityRegistrantName
GUIDED THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
58-2029543
dei Entity Address Address Line1
EntityAddressAddressLine1
5835 Peachtree Corners East
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite B
dei Entity Address City Or Town
EntityAddressCityOrTown
Peachtree Corners
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30092
dei City Area Code
CityAreaCode
770
dei Local Phone Number
LocalPhoneNumber
242-8723
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
51288937 shares
CY2023Q2 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
2000 usd
CY2022Q4 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
48000 usd
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
818000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Revenues
Revenues
44000 usd
CY2022Q2 us-gaap Revenues
Revenues
5000 usd
us-gaap Revenues
Revenues
66000 usd
us-gaap Revenues
Revenues
10000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
42000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
11000 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
4000 usd
us-gaap Gross Profit
GrossProfit
24000 usd
us-gaap Gross Profit
GrossProfit
8000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31000 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
61000 usd
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
37000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
134000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
77000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1389000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
675000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2166000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1062000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1516000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
721000 usd
us-gaap Operating Expenses
OperatingExpenses
2373000 usd
us-gaap Operating Expenses
OperatingExpenses
1170000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1505000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-717000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2349000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1162000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
69000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
256000 usd
us-gaap Interest Expense
InterestExpense
134000 usd
us-gaap Interest Expense
InterestExpense
357000 usd
CY2023Q2 gthp Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
0 usd
CY2022Q2 gthp Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
14000 usd
gthp Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
5000 usd
gthp Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
8000 usd
CY2023Q2 gthp Gain From Extinguishment Of Debt
GainFromExtinguishmentOfDebt
17000 usd
CY2022Q2 gthp Gain From Extinguishment Of Debt
GainFromExtinguishmentOfDebt
34000 usd
gthp Gain From Extinguishment Of Debt
GainFromExtinguishmentOfDebt
52000 usd
gthp Gain From Extinguishment Of Debt
GainFromExtinguishmentOfDebt
75000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-52000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-209000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-77000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-270000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1557000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-926000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2426000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1432000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1557000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-926000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2426000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1432000 usd
CY2023Q2 gthp Deemed Dividend For Warrant Exchanges
DeemedDividendForWarrantExchanges
0 usd
CY2022Q2 gthp Deemed Dividend For Warrant Exchanges
DeemedDividendForWarrantExchanges
0 usd
gthp Deemed Dividend For Warrant Exchanges
DeemedDividendForWarrantExchanges
-65000 usd
gthp Deemed Dividend For Warrant Exchanges
DeemedDividendForWarrantExchanges
0 usd
CY2023Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
47000 usd
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
81000 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
82000 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
629000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1604000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1007000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2573000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2061000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
50970000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
26337000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
50138000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
23526000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50970000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26337000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50138000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23526000 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2855000 usd
CY2023Q2 gthp Common Stock Warrants Exercised Amount
CommonStockWarrantsExercisedAmount
9000 usd
CY2023Q2 gthp Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount
8000 usd
CY2023Q2 gthp Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount
9000 usd
CY2023Q2 gthp Conversion Of Series F Preferred Stock To Common Stock Amount
ConversionOfSeriesFPreferredStockToCommonStockAmount
0 usd
CY2023Q2 gthp Stockbasedcompensation
Stockbasedcompensation
1119000 usd
CY2023Q2 gthp Accruedpreferreddividends
Accruedpreferreddividends
-48000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1557000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3315000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2883000 usd
gthp Common Stock Warrants Exercised Amount
CommonStockWarrantsExercisedAmount
231000 usd
gthp Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount
14000 usd
gthp Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount
8000 usd
gthp Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount
53000 usd
gthp Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount
29000 usd
gthp Conversion Of Series E Preferred Stock To Common Stock Amount
ConversionOfSeriesEPreferredStockToCommonStockAmount
0 usd
gthp Conversion Of Series F Preferred Stock To Common Stock Amount
ConversionOfSeriesFPreferredStockToCommonStockAmount
0 usd
gthp Conversion Of Series F2 Preferred Stock To Common Stock Amount
ConversionOfSeriesF2PreferredStockToCommonStockAmount
0 usd
gthp Issuance Of Common Stock For Payment Of Interest Amount
IssuanceOfCommonStockForPaymentOfInterestAmount
59000 usd
gthp Stock Based Compensation Amount
StockBasedCompensationAmount
1683000 usd
gthp Impact Of Warrant Exchanges
ImpactOfWarrantExchanges
0 usd
gthp Accruedpreferreddividends
Accruedpreferreddividends
-83000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2426000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3315000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-4988000 usd
CY2022Q2 gthp Common Stock Warrants Exercised Amount
CommonStockWarrantsExercisedAmount
130000 usd
CY2022Q2 gthp Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount
13000 usd
CY2022Q2 gthp Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount
26000 usd
CY2022Q2 gthp Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount
2000 usd
CY2022Q2 gthp Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount
12000 usd
CY2022Q2 gthp Conversion Of Series D Preferred Stock To Common Stock Amount
ConversionOfSeriesDPreferredStockToCommonStockAmount
1000 usd
CY2022Q2 gthp Conversion Of Series E Preferred Stock To Common Stock Amount
ConversionOfSeriesEPreferredStockToCommonStockAmount
0 usd
CY2022Q2 gthp Conversion Of Series F Preferred Stock To Common Stock Amount
ConversionOfSeriesFPreferredStockToCommonStockAmount
1000 usd
CY2022Q2 gthp Conversion Of Series F2 Preferred Stock To Common Stock Amount
ConversionOfSeriesF2PreferredStockToCommonStockAmount
0 usd
CY2022Q2 gthp Stockbasedcompensation
Stockbasedcompensation
44000 usd
CY2022Q2 gthp Accruedpreferreddividends
Accruedpreferreddividends
-81000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-926000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-5766000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5445000 usd
gthp Common Stock Warrants Exercised Amount
CommonStockWarrantsExercisedAmount
846000 usd
gthp Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount
29000 usd
gthp Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount
34000 usd
gthp Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount
107000 usd
gthp Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount
IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount
75000 usd
gthp Issuance Of Common Stock For Payment Of Interest Amount
IssuanceOfCommonStockForPaymentOfInterestAmount
81000 usd
gthp Issuance Of Common Stock For Series F And Series F2 One Time15 Dividends Amount
IssuanceOfCommonStockForSeriesFAndSeriesF2OneTime15DividendsAmount
400000 usd
gthp Conversion Of Series D Preferred Stock To Common Stock Amount
ConversionOfSeriesDPreferredStockToCommonStockAmount
1000 usd
gthp Conversion Of Series E Preferred Stock To Common Stock Amount
ConversionOfSeriesEPreferredStockToCommonStockAmount
0 usd
gthp Conversion Of Series F Preferred Stock To Common Stock Amount
ConversionOfSeriesFPreferredStockToCommonStockAmount
0 usd
gthp Conversion Of Series F2 Preferred Stock To Common Stock Amount
ConversionOfSeriesF2PreferredStockToCommonStockAmount
0 usd
gthp Stockbasedcompensation
Stockbasedcompensation
167000 usd
gthp Accruedpreferreddividends
Accruedpreferreddividends
-629000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1432000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-5766000 usd
us-gaap Profit Loss
ProfitLoss
2426000 usd
gthp Bad Debt Expense
BadDebtExpense
2000 usd
gthp Bad Debt Expense
BadDebtExpense
0 usd
us-gaap Depreciation
Depreciation
5000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-937000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-528000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
362000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-955000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-197000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2313000 usd
gthp Settlement Of Interest Through Common Stock Issuance
SettlementOfInterestThroughCommonStockIssuance
59000 usd
gthp Settlement Of Interest Through Common Stock Issuance
SettlementOfInterestThroughCommonStockIssuance
81000 usd
gthp Settlement Of Dividends Through Common Stock Issuance
SettlementOfDividendsThroughCommonStockIssuance
105000 usd
gthp Settlement Of Dividends Through Common Stock Issuance
SettlementOfDividendsThroughCommonStockIssuance
646000 usd
gthp Conversion Of Series D Preferred Shares Into Common Stock
ConversionOfSeriesDPreferredSharesIntoCommonStock
0 usd
gthp Conversion Of Series D Preferred Shares Into Common Stock
ConversionOfSeriesDPreferredSharesIntoCommonStock
118000 usd
gthp Conversion Of Series E Preferred Shares Into Common Stock
ConversionOfSeriesEPreferredSharesIntoCommonStock
5000 usd
gthp Conversion Of Series E Preferred Shares Into Common Stock
ConversionOfSeriesEPreferredSharesIntoCommonStock
800000 usd
gthp Conversion Of Series F Preferred Shares Into Common Stock
ConversionOfSeriesFPreferredSharesIntoCommonStock
42000 usd
gthp Conversion Of Series F2 Preferred Shares Into Common Stock
ConversionOfSeriesF2PreferredSharesIntoCommonStock
426000 usd
CY2023Q2 gthp Working Capital
WorkingCapital
-2900000 usd
CY2023Q2 gthp Retained Earning Accumulated Deficit
RetainedEarningAccumulatedDeficit
-149900000 usd
gthp Net Loss Preferred Dividend
NetLossPreferredDividend
-2600000 usd
CY2023Q2 gthp Preconfirmations Stockholders Equity
PreconfirmationsStockholdersEquity
-3300000 usd
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
194750 usd
CY2022 us-gaap Proceeds From Sale Of Trust Assets To Pay Expenses
ProceedsFromSaleOfTrustAssetsToPayExpenses
3200000 usd
CY2022 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
531878 usd
us-gaap Use Of Estimates
UseOfEstimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes and binomial option pricing models. The Company uses the binomial option pricing model for the calculation of the fair value of embedded conversion options and freestanding warrants with market conditions.
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains a cash balance in a financial institution that is insured by the Federal Deposit Insurance Corporation up to certain federal limitations. At times, the Company’s cash balance exceeds these federal limitations. The amount in excess of insured limitations was approximately $1,109,929 and $2,064,772 as of June 30, 2023 and December 31, 2022, respectively.</p>
CY2023Q2 gthp Excessed Amount Of Insured Limitations
ExcessedAmountOfInsuredLimitations
1109929 usd
CY2022Q4 gthp Excessed Amount Of Insured Limitations
ExcessedAmountOfInsuredLimitations
2064772 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
1295000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1260000 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
58000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
68000 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
38000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
38000 usd
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
818000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
818000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
573000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
548000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1792000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1792000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1756000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1750000 usd
CY2023Q2 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
366000 usd
CY2022Q4 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
444000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
226000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
285000 usd
CY2023Q2 gthp Accrued Stock Subscription Payable
AccruedStockSubscriptionPayable
0 usd
CY2022Q4 gthp Accrued Stock Subscription Payable
AccruedStockSubscriptionPayable
36000 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
131000 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
189000 usd
CY2023Q2 us-gaap Accrued Vacation Current And Noncurrent
AccruedVacationCurrentAndNoncurrent
30000 usd
CY2022Q4 us-gaap Accrued Vacation Current And Noncurrent
AccruedVacationCurrentAndNoncurrent
41000 usd
CY2023Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
210000 usd
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
231000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
8000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
21000 usd
CY2023Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
971000 usd
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1247000 usd
CY2023Q2 us-gaap Deferred Revenue
DeferredRevenue
445444 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
509101 usd
CY2023Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
8942 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1500 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
7442 usd
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
54484 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
48172 usd
CY2022Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
6312 usd
CY2023Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
65600000 usd
us-gaap Premiums Percentage Assumed To Net
PremiumsPercentageAssumedToNet
0.50 pure
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
206306 usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
87823 usd
CY2019Q4 gthp Derivative Liability Bifurcated Conversion Option Actus Loan Amount
DerivativeLiabilityBifurcatedConversionOptionActusLoanAmount
326016 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
-5000 usd
gthp Summary Of Changes To Level3 Instruments
SummaryOfChangesToLevel3Instruments
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(in thousands)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Derivative</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balance at December 31, 2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in fair value during the period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balance at June 30, 2023</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Unit Outstanding
CommonUnitOutstanding
51010579 shares
CY2022Q4 us-gaap Shares Issued
SharesIssued
48595715 shares
us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
2414864 shares
us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
2414864 shares
CY2022Q4 us-gaap Shares Outstanding
SharesOutstanding
48595715 shares
CY2023Q2 us-gaap Shares Outstanding
SharesOutstanding
51010579 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
35586980 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
5873750 shares
gthp Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Warrant Issued
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceWarrantIssued
0.25
gthp Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exchanged
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExchanged
-1025000 usd
gthp Share Based Compensation Arrangement By Share Based Payment Award Options For Exchange In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExchangeInPeriodWeightedAverageExercisePrice
0.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
9478200 shares
gthp Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceExpired
0.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
973750 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.20
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
29983780 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.49
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
2.906 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.037 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2023Q2 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.10 pure
CY2023Q1 gthp Vesting Period Description
VestingPeriodDescription
One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on May 10, 2023
CY2023Q1 gthp Vesting Period Description
VestingPeriodDescription
One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on June 7, 2023
gthp Stock Based Compensation Expense
StockBasedCompensationExpense
206306 usd
gthp Stock Based Compensation Expense
StockBasedCompensationExpense
87823 usd
gthp Outstanding At Beginning Of Year
OutstandingAtBeginningOfYear
1500000 shares
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.49
gthp Weighted Average Remaining Contractual Life Beginning
WeightedAverageRemainingContractualLifeBeginning
P7Y6M
CY2022Q4 gthp Agrregate Intrensic Value
AgrregateIntrensicValue
0 usd
gthp Options Granted
OptionsGranted
1025000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.26
gthp Share Based Compensation Arrangement By Share Based Payment Award Option Forfeiture In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeitureInPeriod
-186364 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.31
gthp Outstanding End
OutstandingEnd
2338636 shares
CY2023Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.41
gthp Weighted Average Remaining Contractual Life Ending
WeightedAverageRemainingContractualLifeEnding
P7Y1M6D
CY2023Q2 gthp Agrregate Intrensic Value
AgrregateIntrensicValue
0 usd
gthp Number Of Shares Exercisable
NumberOfSharesExercisable
1755114 shares
gthp Weighted Average Exercise Price Per Share Exercisable
WeightedAverageExercisePricePerShareExercisable
0.45
gthp Weighted Average Remaining Contractual Life Exercisable
WeightedAverageRemainingContractualLifeExercisable
P6Y2M12D
gthp Agrregate Intrensic Value Exercisable
AgrregateIntrensicValueExercisable
0 usd
gthp Outstanding End
OutstandingEnd
1500000 shares
CY2022Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.49
gthp Weighted Average Remaining Contractual Life Ending
WeightedAverageRemainingContractualLifeEnding
P8Y
CY2022Q2 gthp Agrregate Intrensic Value
AgrregateIntrensicValue
0 usd
gthp Number Of Shares Exercisable
NumberOfSharesExercisable
1136182 shares
gthp Weighted Average Exercise Price Per Share Exercisable
WeightedAverageExercisePricePerShareExercisable
0.49
gthp Weighted Average Remaining Contractual Life Exercisable
WeightedAverageRemainingContractualLifeExercisable
P8Y
gthp Agrregate Intrensic Value Exercisable
AgrregateIntrensicValueExercisable
0 usd
gthp Unrecognized Stock Based Compensation Expense
UnrecognizedStockBasedCompensationExpense
153924 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y9M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.26
gthp Expected Term Years
ExpectedTermYears
P10Y
gthp Fair Value Assumption Expected Volatility Rate
FairValueAssumptionExpectedVolatilityRate
3.664 pure
gthp Fair Value Assumption Risk Free Interest Rate
FairValueAssumptionRiskFreeInterestRate
0.038 pure
gthp Fair Value Assumption Expected Dividend Rate
FairValueAssumptionExpectedDividendRate
0.0000 pure
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
266000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
303000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
287000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
325000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
56000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
115000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
118000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
50000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
339000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
52000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
287000 usd
us-gaap Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension
FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
P2Y10M24D
CY2022 us-gaap Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension
FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
P3Y4M24D
gthp Weighted Average Discount Rateoperating Lease
WeightedAverageDiscountRateoperatingLease
0.114 pure
CY2022 gthp Weighted Average Discount Rateoperating Lease
WeightedAverageDiscountRateoperatingLease
0.114 pure
CY2016Q2 gthp Royalty Percent
RoyaltyPercent
0.20 pure
CY2020Q1 gthp Warrants Broken Into Four Tranches
WarrantsBrokenIntoFourTranches
1250000 shares
CY2020Q1 us-gaap Share Price
SharePrice
0.25
CY2019Q4 us-gaap Share Price
SharePrice
0.40
CY2023Q2 gthp Estimated Fair Value Of The Warrants
EstimatedFairValueOfTheWarrants
800000 shares
gthp Recognized Expenses For The Warrants
RecognizedExpensesForTheWarrants
90344 usd
gthp Unecognized Expenses For Warrants Issued
UnecognizedExpensesForWarrantsIssued
91978 usd
CY2019Q3 gthp Consideration Received
ConsiderationReceived
885144 usd
CY2022Q3 us-gaap Line Of Credit Facility Average Outstanding Amount
LineOfCreditFacilityAverageOutstandingAmount
123889 usd
CY2022Q3 us-gaap Repayments Of Debt
RepaymentsOfDebt
11409 usd
CY2022Q3 gthp Accrued Interest Rate
AccruedInterestRate
0.050 pure
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2023-05-04
CY2022Q4 us-gaap Notes Payable
NotesPayable
56569 usd
CY2023Q2 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
0 usd
CY2022Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
58000 usd
CY2022Q4 gthp Short Term Notes Payable Due To Related Parties
ShortTermNotesPayableDueToRelatedParties
619 usd
CY2019Q4 us-gaap Convertible Debt
ConvertibleDebt
2400000 usd
CY2023Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.24 pure
gthp Convertible Debt Conversion Price Description
ConvertibleDebtConversionPriceDescription
variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date
CY2019Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.04
CY2019Q4 gthp Variable Conversion Price
VariableConversionPrice
0.15
gthp Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
1228183 usd
CY2022Q3 gthp Default Premiums
DefaultPremiums
281256 usd
CY2022Q3 gthp Interest Payable
InterestPayable
91555 usd
CY2022Q3 gthp Amount Reduce After Exchange
AmountReduceAfterExchange
710911 usd
CY2022Q3 gthp Warrant Exchange
WarrantExchange
8775000 shares
CY2022Q3 gthp Early Repayment Of Senior Debt Penalty
EarlyRepaymentOfSeniorDebtPenalty
350000 usd
CY2022Q3 gthp Debt Instrument Default Penalty Forgiven
DebtInstrumentDefaultPenaltyForgiven
225444 usd
CY2023Q2 gthp Senior Unsecured Convertible Debentures
SeniorUnsecuredConvertibleDebentures
1130000 usd
CY2022Q4 gthp Senior Unsecured Convertible Debentures
SeniorUnsecuredConvertibleDebentures
1130000 usd
CY2023Q2 gthp Debt Issuance Costs Amortized
DebtIssuanceCostsAmortized
-26000 usd
CY2022Q4 gthp Debt Issuance Costs Amortized
DebtIssuanceCostsAmortized
-40000 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
89000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
140000 usd
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1015000 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
950000 usd
CY2022Q4 gthp Outstanding Principal Longterm Debt
OutstandingPrincipalLongtermDebt
17052 usd
CY2022Q4 gthp Accrued Interest
AccruedInterest
5139 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2573000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2061000 usd
us-gaap Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma
WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma
50138000 shares
us-gaap Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma
WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma
23526000 shares
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.05
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.09
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
50138000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
23526000 shares
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.05
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.09

Files In Submission

Name View Source Status
0001477932-23-005869-index-headers.html Edgar Link pending
0001477932-23-005869-index.html Edgar Link pending
0001477932-23-005869.txt Edgar Link pending
0001477932-23-005869-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gthp-20230630.xsd Edgar Link pending
gthp_10q.htm Edgar Link pending
gthp_ex31.htm Edgar Link pending
gthp_ex32.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
gthp-20230630_cal.xml Edgar Link unprocessable
gthp-20230630_def.xml Edgar Link unprocessable
gthp-20230630_lab.xml Edgar Link unprocessable
gthp-20230630_pre.xml Edgar Link unprocessable
gthp_10q_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable